Zobrazeno 1 - 10
of 51
pro vyhledávání: '"D. Heger-Mahn"'
Autor:
D. Heger-Mahn, K. Breithaupt-Grögler, M. Mahler, Robert Hermann, C. Klipping, C. de Mey, M. Seibert-Grafe
Publikováno v:
European Journal of Clinical Pharmacology. 53:207-214
Objective: The various good clinical practice (GCP) guidelines do not define the volunteering subject as an active party. The present survey addresses the volunteer's perception of study-related inconvenience and risk and its impact on their decision
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc01e47a474812377703cf3fee3c275d
https://doi.org/10.1007/s002280050364
https://doi.org/10.1007/s002280050364
Publikováno v:
Geburtshilfe und Frauenheilkunde. 56:221-225
The effect of a 26 day oestrogen-gestogene sequence therapy on double endometrium thickness, uterus size, blood flow in the uterine blood vessels (pulsatility and resistance index), serum concentration of FSH, LH and SHBG and on vaginal cytology of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fef464641bfc7a22bb30aed00163273
https://doi.org/10.1055/s-2007-1022263
https://doi.org/10.1055/s-2007-1022263
Publikováno v:
Advances in Contraception. 11:207-225
The study was performed in 14 young women. The combination oral contraceptive contained 75 microgram gestodene (GSD) and 20 microgram ethinyl estradiol (EE2) per dosage unit. The volunteers received a single dose on day 21 of a treatment-free precycl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fc43f7e6233ba435018b711ea7dc333
https://doi.org/10.1007/bf01978421
https://doi.org/10.1007/bf01978421
Autor:
C, Klipping, D, Heger-Mahn
Publikováno v:
International journal of clinical pharmacology and therapeutics. 36(11)
The study populations taking part in early clinical drug development of reproductive endocrine treatments are discussed. After having compared subjects in phase I studies with subsequent target populations, the question was posed as to whether the in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::97d8c60628e3c33898a3175aa545ae01
https://pubmed.ncbi.nlm.nih.gov/9849748
https://pubmed.ncbi.nlm.nih.gov/9849748
Autor:
R, Hermann, D, Heger-Mahn, M, Mahler, M, Seibert-Grafe, C, Klipping, K, Breithaupt-Grögler, C, de Mey
Publikováno v:
European journal of clinical pharmacology. 53(3-4)
The various good clinical practice (GCP) guidelines do not define the volunteering subject as an active party. The present survey addresses the volunteer's perception of study-related inconvenience and risk and its impact on their decision to enroll.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::928fad5b0b87c44785f4d8cad55ff6dd
https://pubmed.ncbi.nlm.nih.gov/9476033
https://pubmed.ncbi.nlm.nih.gov/9476033
Publikováno v:
Geburtshilfe und Frauenheilkunde. 56(5)
The effect of a 26 day oestrogen-gestogene sequence therapy on double endometrium thickness, uterus size, blood flow in the uterine blood vessels (pulsatility and resistance index), serum concentration of FSH, LH and SHBG and on vaginal cytology of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b6a5223eb49012d6b0a7af0176a84b70
https://pubmed.ncbi.nlm.nih.gov/8768057
https://pubmed.ncbi.nlm.nih.gov/8768057
Publikováno v:
Arzneimittel-Forschung. 45(3)
A questionnaire was completed by members of the Association for Applied Human Pharmacology (AGAH) in Germany with the aim of assessing the present situation regarding management of adverse events (AEs). A recommendation for documentation and evaluati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::97774555aab04926bb032826db1e56e9
https://pubmed.ncbi.nlm.nih.gov/7741796
https://pubmed.ncbi.nlm.nih.gov/7741796
Publikováno v:
Journal of the American Academy of Dermatology. 29(4)
Background: The therapy for skin diseases with topical glucocorticoids is limited by their local and systemic side effects. A glucocorticoid with an improved benefit-to-risk ratio is desirable. Objective: A new topical corticoid, methylprednisolone a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f49aaa49fc34b354616715973255fc4d
https://pubmed.ncbi.nlm.nih.gov/8408793
https://pubmed.ncbi.nlm.nih.gov/8408793
Autor:
D. Heger-Mahn
Publikováno v:
Good Clinical Practice II ISBN: 9783642847301
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f029c2d3480af74dc925105b393ec6e0
https://doi.org/10.1007/978-3-642-84729-5_12
https://doi.org/10.1007/978-3-642-84729-5_12
Autor:
D. Heger-Mahn
Publikováno v:
Good Clinical Practice II ISBN: 9783642847301
Wortlaut des § 40 Abs. 1 Nr. 2 AMG: „Eine klinische Prufung eines Arzneimittels darf beim Menschen nur durchgeshrt werden, wenn die Person, bei der sie durchgefuhrt werden soll, ihre Einwilligung hierzu erteilt hat, nachdem sie durch einen Arzt ub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60289cece14db78fbf38fe71dfff6469
https://doi.org/10.1007/978-3-642-84729-5_9
https://doi.org/10.1007/978-3-642-84729-5_9